BioMarin CSO Lon Cardon adds portfolio strategy to his plate

Before joining BioMarin, Cardon spent nine years at GlaxoSmithKline, most recently heading up target sciences, as well as alternative discovery and development. (BioMarin)

BioMarin Pharmaceutical’s top scientist is expanding his purview—CSO Lon Cardon, Ph.D., is now the rare disease specialist’s chief scientific strategy officer, taking charge of the company’s product portfolio, as well as its research. 

With a clutch of approved treatments for diseases such as phenylketonuria (PKU) and multiple forms of mucopolysaccharidosis (MPS), BioMarin is looking to its pipeline for growth. Its most advanced clinical programs—treatments for achondroplasia, or short-limbed dwarfism, and hemophilia A—are in phase 3. It also has a program in Sanfilippo syndrome, a type of MPS, in phase 2 and a gene therapy for PKU that’s in preclinical studies. 

In his newly minted role, Cardon will lead “cross-functional activities” to drive long-term growth through this pipeline, BioMarin said in a statement. 

Survey

Industry Insight Survey: Direct-to-Patient Distribution of Clinical Supplies

This industry survey seeks to gain insight on trial sponsors' perspective on offering a DTP option and their current level of awareness and understanding of any factors that may influence their ability to do so. The first 50 qualified respondents will receive a $5 Amazon gift card.

RELATED: How did BioMarin pick Brineura, this year's #FierceMadness drug-name champ?

“Lon will support our company's growth by identifying the right balance of resources within BioMarin to move the most promising molecules through our pipeline," said BioMarin CEO Jean-Jacques Bienaimé in the statement. "Lon has done an outstanding job of building our research capabilities positioning BioMarin for future success and brings his knowledge in genetics and drug discovery generally and specifically in BioMarin's scientific expertise to this role." 

Before joining BioMarin, Cardon spent nine years at GlaxoSmithKline, most recently heading up target sciences, as well as alternative discovery and development. He also chaired the Big Pharma’s discovery board, which oversaw the growth of all of its programs, from those in the preclinical stage through those in phase 2. 

RELATED: BioMarin drops lower dose of its hemophilia gene therapy as it eyes submissions by year-end

"I have worked closely with Lon over the past two years and have the utmost confidence in his abilities to oversee a critical part of our business that drives our future growth," said Hank Fuchs, M.D., BioMarin’s president of worldwide R&D. "He is uniquely qualified to champion science at BioMarin that has the potential to change the practice of medicine and to bring together cross-functional teams that will deliver potentially life-changing medicine to patients with rare diseases." 

Cardon’s promotion comes a year-and-a-half after BioMarin logged its latest FDA approval, for the PKU drug Palynziq, and two months after it dropped a lower dose of its hemophilia A gene therapy from clinical development. The company plans to file the blood disorder treatment valoctocogene roxaparvovec by the end of the year. If all goes well, it will be the first gene therapy product to be reviewed in any hemophilia indication.

Suggested Articles

Working with a joint venture established by BMS and Pfizer, Fitbit also plans to help develop educational content regarding atrial fibrillation.

Plexium is launching with $28 million to build its platform and a pipeline of drugs that target the enzymes drive recognition of protein targets.

In this week's EuroBiotech Report, Healx raises $56 million, Boehringer's VC wing backs anti-cancer virus startup and Ipsen bags Blueprint drug.